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Abstract
Chronic back pain is a complex process and similar to how each patient has a very indi‐
vidualized disease process the treatment regimen should be similarly individualized. 
There are several different medication classes, each with a unique mechanism of action 
that can assist the practitioner in targeting a specific aspect of a patient's pain. The goal of 
this chapter will be to provide an adequate overview of the different medication classes 
while providing enough drug‐specific information to guide the practitioner in selecting 
and developing an adequate multimodal analgesic regimen. When designing an analge‐
sic regimen, an emphasis should be placed using a modified stepwise approach similar 
to the World Health Organization's analgesic ladder. There should be a focus on a multi‐
modal analgesia utilizing nonopioid medications for chronic pain. Patient‐specific factors 
should always be considered when choosing class, strength, dosage form and possible 
adjuvant medications. Just like patients, no analgesic regimen should be exactly the same.
Keywords: analgesics, paracetamol, nonsteroidal anti‐inflammatories, neuropathic 
pain, opioids
1. Introduction
Chronic back pain is a complex process and similar to how each patient has a very individu‐
alized disease process the treatment regimen should be similarly individualized. There are 
several different medication classes, each with a unique mechanism of action that can assist 
the practitioner in targeting a specific aspect of a patient's pain. Additionally, patient‐specific 
factors must be considered when developing a regimen to ensure adherence and improve 
outcomes. The goal of this chapter will be to provide an adequate overview of the steps a 
practitioner needs to take during the regimen development process and share enough drug‐
specific information to guide the practitioner in selecting the most efficacious and best suited 
agents for the individual patient.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licen es/by/3.0), w ich permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Prior to initiating any pharmacologic treatment regimen for a patient, current consensus 
recommendations include discussing realistic expectations with the patient [1]. This should 
include patient's expectations of pain relief as well as functional goals that the patient should 
work toward. Additionally, the clinician should encourage self‐care and education with evi‐
dence‐based materials. It is important to emphasize to the patient that acute low back pain has 
very favorable improvement in the first month of recovery. Generally speaking, staying active 
and exercising should be highly encouraged for all patients. Bed rest should only be recom‐
mended if it improves severe pain symptoms and its duration should only be temporary. 
Patients should also be encouraged to resume activity as quickly as possible.
2. Multimodal and targeted treatment approaches
There are several important concepts that a clinician must understand before they can ade‐
quately start the treatment of low back pain. The first is that there is more data on the use of 
medication for acute low back pain than chronic low back pain [1]. This does not mean that 
specific pharmacologic agents are not effective in the setting of chronic low back pain, but 
simply that there is less evidence due to constraints in studying the long‐term side effects [1]. 
When initiating the therapy, the clinician should focus on medications with the most known 
efficacy for the specific cause of pain and that have the least risk for serious side effects [1]. 
Specifically, the drug class and sometimes the even the individual drug chosen will be dic‐
tated by side effects (short and long term) and targeted mechanism of pain.
Treatment should include a targeted approach to the individual's cause of low back pain. The 
majority of low back pain is caused by a mechanical etiology [2]. These causes include degen‐
erative disk or joint disease, vertebral fracture, and deformities and occur in up to 80–90% 
of patients. Neurogenic (e.g., herniated disks, spinal stenosis) inflammatory (e.g., rheuma‐
toid arthritis, ankylosing spondylitis) and other less common causes (e.g., neoplasm, referred 
pain) make up the remainder of etiologies. The pharmacologic agents first selected should 
be completely dependent on the underlying etiology. However, as the pain progresses to a 
chronic state, a broader approach typically must be taken due to decreased efficacy of the 
targeted treatment.
The majority of this chapter will focus on the treatment of low back pain with an underlying 
mechanical etiology since it is by far the most common. However, if the cause of low back 
pain is inflammatory in nature, targeted therapy should also focus on treatment with anti‐
inflammatory agents. This may mean early use of nonsteroidal anti‐inflammatories (NSAIDs) 
and treatment with corticosteroids or disease‐modifying antirheumatic drugs (DMARDs) in 
patients with rheumatoid arthritis or ankylosing spondylitis [3]. Additionally, these disease 
states have a higher incidence of neuropathic pain and thus may require adjuvant medica‐
tions that target this specific pain type. Some patients with mechanical low back pain also 
have increased pain due to spasticity and may benefit from treatment with antispasmodics. 
These agents will be discussed in much greater detail later, but to put it simply treatment 
should be tailored to the individual.
Pain Relief - From Analgesics to Alternative Therapies184
While the treatment of acute low back pain is normally fairly straight forward, its progression 
into chronic pain tends to complicate treatment. This is primarily due to the fact that chronic 
pain can often be associated with not only physical pain, but also deleterious cognitive and 
behavioral effects [4]. Because of this, a patient's rehabilitation program should emphasize 
a biopsychosocial model or one that involves a combination of physical, psychological and 
educational components [4, 5]. This also means that treatment (including medications) should 
be used to treat any psychological processes that may be worsening the perception of pain 
such as depression or anxiety.
Lastly, it is important to understand that medication alone will likely not completely allevi‐
ate a patient's pain, and it is even less likely to do so if the pain is chronic. Thus, treatment 
as a whole should be tailored to the individual and a holistic approach should be taken [4]. 
In addition to pharmacologic treatments, nonpharmacologic treatments including topical 
heat for acute pain or cognitive behavioral therapy, exercise therapy, spinal manipulation 
and interdisciplinary rehabilitation for subacute or chronic pain should be considered [6, 7]. 
However, for the purpose of this chapter, we will be focusing primarily on pharmacologic 
treatments and how they should be combined, implemented and optimized.
3. World Health Organization's stepwise approach to pain
In 1986, the World Health Organization (WHO) published an analgesic treatment model that 
described in detail the appropriate way to escalate therapy in chronic pain associated with 
cancer [8]. This stepwise model focused on the incremental escalation of treatment from non‐
opioid analgesics to low‐strength opioids and eventually to medium‐ or high‐strength opi‐
oids. Since its publication this model has been adapted into the treatment of all types of pain 
including acute, chronic and noncancer pain [9]. Many attribute this to the increased opioid 
utilization for the management of all types of pain [10]. Additionally, many argue that opioid 
medications are being over utilized and the stepwise approach, while simple, is not the most 
ideal method in treating chronic pain. Even if the stepwise model is not perfect in its original 
form, several key components should be considered when implementing or modifying an 
analgesic treatment regimen [9].
Whether the patient has acute or chronic pain, a couple of components of the WHO's stepwise 
approach are critical to follow no matter the circumstance [9]. These key aspects include that 
the prescriber should utilize oral medications whenever possible, prescribe analgesics at fixed 
intervals dictated by their duration of action, the specific analgesic chosen should be dependent 
on pain intensity and its effect should be evaluated by a validated pain intensity scale [8]. When 
looking at the complete analgesic regimen, it should be uniquely tailored to the individual 
and once a regimen is established, a written personal program should be given to the patient, 
so they can be held accountable to taking medications at their appropriate times and others 
(family, friends and medical professionals) know how they take their medications in case of 
emergency. While these components should be cemented in the care of any patient with low 
back pain, the ideal stepwise escalation, de‐escalation or type of adjuvant medication depends 
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upon the type of pain being treated and may not follow the originally proposed WHO's step‐
wise approach [9].
Several recommendations have been suggested for the alteration of the WHO's stepwise 
approach to pain [9]. The first is that when dealing with acute pain, it is sometimes necessary 
to start at a higher step than the first step of the ladder. This means that opposed to starting 
with a nonopioid agent alone, it may be necessary to start therapy with a weak, moderate 
or even strong opioid in addition to a nonopioid agent. However, because most acute pain 
resolves or markedly improves in a short period of time, there should be an emphasis on early 
alteration of the analgesic regimen. Rarely are opioids needed for longer than 7 days to treat 
acute pain [6]. The one major stipulation to treating acute pain in this way (skipping steps on 
the WHO's ladder) is that the provider is encouraged to rapidly step down the ladder or de‐
escalate therapy as pain diminishes or side effects are too severe. This requires a practitioner 
to have very close follow‐up and may not be appropriate in all settings. This recommendation 
is not originally recommended by the WHO, but it is feasible when considering the acute pain 
process and the need to wean patients from regimens containing strong opioids [9].
As the patient transitions from an acute pain process to a chronic pain state (1–3 months), it is 
import to reassess the analgesic regimen. If de‐escalation has not been performed, it should be 
done at this point to ensure that the patient is only prescribed the minimal amount of medi‐
cations required to control their pain. When escalating in a stepwise manner, the cause and 
type of pain should be considered. The pain regimen should focus on nonopioid analgesics 
with nonsteroidal anti‐inflammatories (NSAIDs) if the pain is caused or exacerbated by an 
inflammatory process. Adjuvant medications targeting neuropathic pain should be initiated 
and optimized at this time if there is a component of neuropathic pain [9]. Only when nono‐
pioids and adjuvant medications have been fully optimized, an opioid should be scheduled 
at a fixed interval. Nonpharmacologic and nonopioid medications are preferred for chronic 
pain [6]. If the pain requires opioids, a weak opioid should be trialed first before escalating to 
a moderate or strong opioid [8, 9]. To appropriately escalate therapy, it is necessary to under‐
stand the specific attributes of each analgesic medication (nonopioids, opioids and adjuvants) 
so that the patient receives the maximum benefit while minimizing the potential for harm and 
side effects.
4. Paracetamol/acetaminophen
Paracetamol, also commonly referred to as acetaminophen, was first synthesized in 1878 
by Morse, a researcher at Johns Hopkins Hospital [11]. It was not until 15 years later that 
paracetamol's antipyretic effects were first noted and a medical implication was suggested 
[11, 12]. The current consensus is that paracetamol is the first‐line agent for both acute pain 
and chronic pain [1, 6, 11]. This is not because paracetamol is a more potent analgesic, but 
because it has a much better side effect profile than that of other nonopioid analgesics [1, 11].
Even though it has been well over a hundred years since its synthesis, not much is known 
about the mechanism of action of paracetamol and several have been proposed to explain 
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paracetamol's antipyretic and analgesics effects [11–13]. One in particular is that it indirectly 
inhibits the cyclooxygenase (COX) enzymes. The COX isoenzymes are responsible for con‐
verting arachidonic acid to prostaglandins, thromboxanes and prostacyclins. Prostaglandins 
are thought to be a primary mediator of pain, fever and inflammation both centrally and 
peripherally. Paracetamol is thought to only inhibit a certain isoenzyme of COX (COX‐3) in 
the brain which is why many believe that it has minimal anti‐inflammatory effects in periph‐
eral tissues [11, 14]. While there are high concentrations of COX‐1 and COX‐2 in peripheral 
tissue, the proposed COX‐3 enzyme is thought to have higher concentrations in the brain. It is 
through the inhibition of COX‐3 that paracetamol may have its primary mechanism of action 
causing analgesic and antipyretic effects while exerting minimal anti‐inflammatory effects 
[11, 12]. While this is a popular hypothesis, it does not explain the small amount of peripheral 
anti‐inflammatory activity some researchers have found.
Another proposed hypothesis postulates that paracetamol inhibits COX isoenzymes in a 
unique manner and explains the mild anti‐inflammatory effects it may have. Unlike NSAIDs, 
this hypothesis suggests paracetamol does not bind to the active site of COX to cause inhibi‐
tion [11]. It instead reduces COX from its active form (Fe4+) to its inactive form (Fe3+) and in 
turn prevents the conversion of arachidonic acid to prostaglandins. Paracetamol's reducing 
effects are blocked by locally acting peroxides. This explains why paracetamol may be inacti‐
vated in the periphery where there are high levels of peroxides in the setting of cell damage, 
but not centrally where levels are significantly lower.
Side effects of paracetamol are relatively benign with the most worrisome being hepatotox‐
icity caused by toxic levels of its metabolite N‐acetyl‐p‐benzoquinineimine (NAPQI) [11, 
14]. Close to 40% of all acute liver failure cases in the United States and United Kingdom 
can be attributable to paracetamol intoxication. Approximately 90% of paracetamol is 
metabolized in the liver through glucuronidation or sulfation. The remainder of the drug's 
metabolism through the liver is through the cytochrome P450 (CYP450) system. The spe‐
cific subfamily that has been implicated in the majority of this process is CYP2E1. As the 
glucuronidation and sulfation pathways are saturated, the metabolism through the CYP450 
system proportionately increases and more NAPQI is produced. NAPQI then exerts its 
toxic effects by binding covalently to macromolecules of hepatocytes. Total daily doses of 
paracetamol alone or in combination with other analgesics should not be greater than 4 g 
a day with most regimens being 325–650 mg given every 4–6 h [1, 11, 15]. However, recent 
increases in the use of paracetamol‐containing combination products have brought concern 
to overdose risk. Due to this, some clinicians recommend a maximum daily dose of 2.4–3.2 g 
a day, especially in the elderly [16–18]. Of note, paracetamol is commonly combined with 
opioid analgesics and is found to have additive analgesic effects when done so. The risk for 
overdose is increased in this setting due to patients taking paracetamol alone in addition to 
the combination product. In 2011, the Food and Drug Administration (FDA) of the United 
States limited the amount of paracetamol to 325 mg in combination products due to this 
increased risk.
Other patient populations at risk for toxicity include those that are malnourished, those tak‐
ing CYP450 inducers (isoniazid, anticonvulsants) and those with heavy alcohol consumption 
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[11, 14]. Chronic alcoholism is especially worrisome for patients taking high doses of paracetamol 
on a daily basis. Chronic alcohol intake causes hepatotoxicity through a completely indepen‐
dent pathway as well as increasing CYP450 activity and depleting glutathione stores. Both of 
these increase the production of NAPQI. Therefore, in alcoholics, total daily doses should be 
limited to 2 g [18].
Other less common, but notable side effects of paracetamol therapy include hypersensitiv‐
ity reactions and elevations in international normalized ration (INR) [11, 18, 19]. When 
patients were given 4 g of paracetamol a day for 14 days, there was a mild increase in INR 
as well as a mild decrease in vitamin K‐dependent clotting factors. This supports closer 
monitoring when patients are being co‐administered warfarin and paracetamol for long 
periods of time. Intravenous doses of 1 g have been shown to cause very minor decreases 
in platelet aggregation, but overall paracetamol should be considered safe to use in the 
setting of an elevated bleeding risk. It is because of the lack of side effects and relative 
tolerability of paracetamol that it is recommended as the first‐line agent in treating acute 
and chronic pains.
5. Nonsteroidal anti‐inflammatories
Similar to paracetamol, NSAIDs exert their analgesic, antipyretic and anti‐inflammatory 
effects through the inhibition of COX isoenzymes [18, 20]. NSAIDs specifically target COX‐1 
and COX‐2, and enzyme affinity varies among agents. It is this isoenzyme selectivity that 
determines the efficacy and safety profile of these agents. As a group, NSAIDs typically 
are used as second‐line agents in the treatment of acute and chronic low back pains after 
paracetamol [1, 7]. NSAIDs are more potent analgesics when compared to paracetamol for the 
treatment acute pain, but they are also associated with gastrointestinal, renal and cardiovas‐
cular complications with chronic use [14, 21]. At high doses, NSAIDs can even have compa‐
rable analgesic effects to low‐dose opioids without the respiratory depressant effects. When 
evaluating the clinical efficacy among NSAIDs, no study has shown that one agent is better 
than another [20]. Therefore, when selecting an agent, careful consideration of each agent's 
safety and pharmacokinetic profile should be considered.
There are several different classes of NSAIDs, and most classes have multiple agents as well. 
For the purposes of this chapter, we will be focusing on those agents commonly used to treat 
acute and chronic pains. In order to treat low back pain effectively, an NSAIDs must be avail‐
able orally and have good bioavailability, a fast onset of action, convenient dosing interval 
and minimal drug‐drug interactions (Table 1). Of note, several NSAIDs (diclofenac, ibupro‐
fen and ketoprofen) have topical formulations that likely provide similar analgesic effects as 
their oral counter parts, but are associated with less systemic side effects [22]. Additionally, 
other dosage forms may be available to treat acute pain in patients unable to take oral medi‐
cations. For example, there are intravenous formulations of ketorolac and ibuprofen that can 
be used in the hospitalized setting to treat acute pain. Similarly, rectal formulations are also 
available for several NSAIDs, but their long‐term use for analgesia is inconvenient and com‐
parative efficacy is unknown.
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Drug name Dosage forms Typical dose (mg) Dosing interval (h) COX selectivity Comments
Ketorolac Oral; 
intravenous
10 4–6 COX‐1 Potent analgesic
Ketoprofen Oral (immediate 
release, extended 
release);
Gel
Immediate release: 
25–50;
Extended release: 100
Immediate release: 
6–8
Extended release: 24
COX‐1 High incidence 
of GI side effects; 
maximum dose 
of 100 mg in 
patients with 
renal dysfunction
Indomethacin Oral (immediate 
release, controlled 
release); 
Intravenous; 
Suppository
Immediate release: 25;
Controlled release: 75
Immediate release: 
8–12;
Controlled release:
COX‐1 High occurrence 
of headache as a 
side effect
Nabumetone Oral 500–1000 12–24 COX‐1 Long half‐life 
(24 h) requires 
fixed interval 
dosing for best 
efficacy; well 
tolerated with 
less GI side 
effects; Variable 
dose reductions 
based on 
degree of renal 
dysfunction
Sulindac Oral 150–200 12 Unselective Undergoes 
enterohepatic 
recirculation
Naproxen Oral (immediate 
release, extended 
release);
Cream
Immediate release: 
250–500; Extended 
release: 750
Immediate release: 
12; Extended 
release: 24
Unselective Long half‐life 
(14 h) analgesic 
effect increases as 
it reaches steady‐
state (3 days)
Piroxicam Oral 20 24 Unselective Very long half‐
life (45–50 h) 
need to take on 
fixed interval for 
best efficacy
Ibuprofen Oral; Cream; 
Intravenous; 
Suppository
200–600 6–8 Unselective Very well 
tolerated at lower 
doses
Diflunisal Oral 500–1000 8–12 Unselective Weak antipyretic 
effects; excreted 
into breast milk
Meloxicam Oral 7.5–15 24 COX‐2 COX‐2 selective 
at lower doses; 
long half‐life 
(20 h) requires 
fixed interval 
dosing for best 
efficacy
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The most common adverse reactions with chronic NSAID use are those associated with the 
upper GI tract [13, 19, 20]. These adverse reactions are dose dependent in nature, and patients 
are placed at increasing risk as doses are escalated for increased analgesia activity. For exam‐
ple, when ibuprofen is used at doses of 800–1200 mg a day, risk for GI bleed was not signifi‐
cantly different than placebo [13]. Additionally, as doses are escalated, the odds of a GI bleed 
nearly double when doses of ≤600 mg/day were compared to doses of >1200 mg/day [19]. 
Adverse reactions are uncommon with chronic NSAID use, with up to 20% of patients report‐
ing dyspepsia during treatment [18, 20]. Other common adverse reactions include anorexia, 
nausea, abdominal pain and diarrhea.
GI adverse reactions are mediated through two possible mechanisms [18, 20]. Through inhibi‐
tion of COX‐1, NSAIDs decrease cytoprotective prostaglandin production in the gastric epi‐
thelial cells. This causes an increase in acid secretion, a decrease in mucosal blood flow and 
a decrease in the production of the protective mucous layer. The second proposed mecha‐
nism is through local irritation to mucosal cells. NSAIDs are week acids, and in the acidic 
environment of the stomach, they stay unionized and readily diffuse into mucosal epithelial 
cells. Once inside cells, these acids trap hydrogen ions and cause cell damage. Risk factors 
for NSAID‐induced GI injury include age > 65 years, tobacco use, alcohol consumption, con‐
current use of steroids, anticoagulation, prior history of GI ulceration and increasing dose or 
duration of NSAIDs. Of note, formulations whose goal is to decrease direct contact with gas‐
tric mucosa (e.g., enteric coating) have not shown to reduce the incidence of major GI adverse 
reactions. However, it is recommended to utilize acid suppression therapy (histamine blockers 
Drug name Dosage forms Typical dose (mg) Dosing interval (h) COX selectivity Comments
Diclofenac Oral (immediate 
release, 
extended 
release);
Suppository; Gel
Immediate release: 
25–50; Extended 
release: 50–75
Immediate release: 
6–8; Extended 
release: 24
COX‐2 Edema is a 
common side 
effect (33% of 
patients)
Celecoxib Oral 100–200 12 COX‐2 Dose reduction 
is necessary in 
CYP2C9 poor 
metabolizers 
(*3/*3 allele) 
although not 
commonly 
known; May 
carry higher 
cardiovascular 
risk than other 
nonselective 
NSAIDs
Etodolac Oral (immediate 
release, 
extended 
release)
Immediate release: 
200–400; Extended 
release: 400–1000
Immediate release: 
6–8; Extended 
release: 24
COX‐2 Similar COX‐2 
selectivity as 
celecoxib
Table 1. Properties of common NSAIDs (ordered in increasing COX‐2 selectivity).
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or proton pump inhibitors) in patients on chronic high doses of NSAIDs to aid in the preven‐
tion of gastric and duodenal ulcers [18, 19].
Due to these common side effects, a subset of NSAIDs was developed to selectively inhibit only 
the COX‐2 isoenzyme. There are much lower concentrations of COX‐2 in the upper GI tract, 
and by sparing inhibition to COX‐1, the detrimental effects seen with nonselective NSAIDs on 
the GI mucosa are greatly diminished [19, 20]. Fortunately, this selective inhibition of COX‐2 
does not seem to decrease the analgesic effects of COX‐2 selective NSAIDs when compared 
to nonselective NSAIDs [23]. However, because there are higher concentrations of COX‐2 in 
cardiovascular (CV) tissue, COX‐2 selective NSAIDs have been associated with increased CV 
risk. This has led to the majority of COX‐2 selective agents to being pulled from the market 
[13]. With this consideration in mind, COX‐2 selective NSAIDs may be advantages in patients 
with history of GI ulcers, dyspepsia, gastroesophageal reflux disease or other similar disor‐
ders and are otherwise good candidates for treatment with NSAIDs [20]. Similar to nonselec‐
tive NSAIDs, use in the setting of acute pain is reasonable, but careful consideration must be 
made when used chronically as long‐term risk likely outweighs benefit.
Another adverse effect of NSAIDs that goes hand in hand with the increased risk for GI 
adverse reactions is the risk of platelet inhibition. Through inhibition of the COX‐1 isoenzyme, 
NSAIDs attenuate the production of thromboxane A2 [19]. By decreasing the production of 
thromboxane A2, NSAIDs reversibly inhibit platelet aggregation and clot formation and if 
combined with other drugs that carry a bleeding risk the effect is additive. One case‐control 
study that looked at NSAID use combined with selective serotonin reuptake inhibitors found 
that the incidence of upper GI bleed or ulcer was three when the agents were used alone [24].
Other limiting factors shown with chronic therapy include an increased cardiovascular throm‐
botic risk, blood pressure and renal toxicity. While each of these adverse events occurs sepa‐
rately, they are intertwined through pathophysiology. CV risk is likely caused by decreased 
production of COX‐2‐dependent prostaglandins in the kidney. These prostaglandins nor‐
mally blunt the effect that prothrombotic and atherogenic inputs have on the coronary vas‐
culature [25]. Without this protection, the risk for CV‐related events elevates. Blood pressure 
and renal toxicity are affected in a somewhat similar matter. In patients who have increased 
activation of the renin‐angiotensin and elevated blood pressure, NSAIDs disrupt the tenuous 
balance that renal prostaglandins play a key role in maintaining homeostasis. When COX‐2 
is inhibited and these prostaglandins are reduced, antidiuretic hormone is blunted and chlo‐
ride ions are reabsorbed to a greater degree. This causes sodium and water retention and 
an elevation in blood pressure [18]. A similar process is commonly described to explain the 
NSAID‐induced renal injury. The same prostaglandins that regulate chloride reabsorption 
also maintain renal blood flow. Homeostasis normally occurs through reducing the effects 
of adrenergic or renin‐angiotensin inputs. When removed, arterial constriction occurs, blood 
supply decreases and renal toxicity occurs [26].
Even with a large number of potential side effects, NSAIDs are a great option to treat low back 
pain, especially if it is only for a short duration. Caution should be advised when consider‐
ing treating for longer durations and when a patient has co‐morbid disease states or is at risk 
for adverse reactions. If it is used chronically, make sure the lowest efficacious dose is being 
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used. Additionally, if a clinician commonly prescribes NSAIDs, they should be diligent in 
following new evidence on efficacy and safety of individual agents to assist them in select‐
ing the most ideal one. When considering a patient's analgesic regimen, NSAIDs are a viable 
first‐ or second‐line treatment choice if the risks for drug‐related complications are low [1, 6]. 
In relation to the WHO's stepwise ladder, adding a NSAID is especially useful if a patient has 
an acute increase in pain (acute injury, worsening breakthrough pain, etc.) and even more so 
if the acute pain process has an inflammatory component. Ideally, when the acute pain event 
is resolved or mitigated, the clinician can shift back down the pain ladder and remove the 
NSAID from the regimen.
6. Adjuvant medications
Medications that fall into the adjuvant medication category have a unique place in therapy. 
These medications typically fall into two categories and can be added at any point in therapy 
(any step of the WHO's analgesic ladder). They should be used to tailor treatment and are a 
mainstay in the targeted treatment of the individual. The two categories are drugs that target 
neuropathic pain and drugs that target somatic pain through an indirect mechanism [8, 10]. 
When initiating an adjuvant medication, it should have a clear target and purpose to aid in 
decreasing pain. Adjuvants should not be used simply to lower opioid requirements, espe‐
cially in patients, on lower doses, with minimal side effects as most adjuvants are not benign 
and many have severe side effects themselves [27].
Neuropathic pain is a type of pain that originates through a dysfunction in the peripheral or 
central nervous system [28, 29]. It is estimated to effect up to 7–8% of the general population 
in Europe and is often so severe that it is disabling to patients. It can be caused by several dif‐
ferent disease processes including chronic radiculopathy and has a high incidence in low back 
pain caused by inflammatory causes.
Gabapentin and pregabalin exert their mechanism of action through binding to voltage‐gated 
calcium channels and result in a decrease in release of the neurotransmitters glutamate and 
substance P [27, 28]. These agents are commonly considered first‐line agents due to their high 
efficacy and a relatively benign side effect profile. Efficacy seems to increase as dose increases, 
but so do side effects. Most commonly, patients experience dizziness, sedation, peripheral 
edema and dry mouth [30]. Both agents can aid in sleep disturbances, and pregabalin has a 
mild anxiolytic effect as well. These agents have also been used in acute pain and are now 
recommended in the postoperative setting with more clinicians claiming these agents should 
be used as true analgesics and not as adjuncts [31].
Antidepressants can alter pain through several different mechanisms. These include modula‐
tion of monoamine activation, interacting with opioid pathways, inhibiting descending pain 
pathways and blocking ion channels that are important in pain transmission [27]. Tricyclic 
antidepressants (TCAs) have the most robust evidence to support their use in neuropathic 
pain. While the exact mechanism is unknown, it is likely mediated through blocking the 
reuptake of norepinephrine. These agents are antagonistic at N‐methyl‐D‐aspartate (NMDA) 
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receptors and may have a roll at reducing hyperalgesia caused by central windup. Agents in 
this class include the secondary amines nortriptyline and desipramine and tertiary amines 
amitriptyline and imipramine. When compared to each other, no agent has been found to be 
superior to another. Despite this, nortriptyline and desipramine are typically considered the 
preferred agents due to better side effect profile. TCAs are associated with increased risk for 
sedation, orthostatic hypotension, dry mouth, constipation, urinary retention and cognitive 
impairment especially in the elderly [15, 23, 28].
TCAs are not the only antidepressants that have been looked at for the treatment of neuro‐
pathic pain. SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs) have also been 
evaluated. Even though the SSRIs citalopram and paroxetine have shown efficacy in treating 
neuropathic pain, they are typically not as preferred compared to TCAs and SNRIs because 
they are less efficacious [28]. Previously, TCAs had been preferred due to more evidence and 
lower costs. However, costs of both venlafaxine and duloxetine have decreased recently and 
use has increased. Some guidelines even support their use as first‐line agents [29]. Of the 
two, duloxetine seems to be preferred because it is associated with less hypertension and is 
well tolerated in the elderly [16, 28, 29]. Patients should be counseled on the fact that treat‐
ing pain with antidepressants can take up to 2.5 weeks to reach their full effect and this can 
decrease compliance.
Other common adjuvant medications commonly added to analgesic regimens include muscle 
relaxants, corticosteroids, local anesthetics and topical agents [27, 32]. Muscle relaxants as a 
group have varying mechanisms of action, some of which are not fully understood. These 
agents may be considered for acute pain relief, but have very limited data to support con‐
tinued use. They should only be used in patients who have increased somatic pain due to 
spasticity. The primary side effect of this drug class is central nervous system adverse effects 
(sedation, fatigue, dizziness, etc.), but because these drugs are not related in mechanism, 
they each have their own safety profiles. Due to the lack of data and risk for severe side effects 
(e.g., hepatotoxicity of dantrolene) use of skeletal muscle relaxants for back pain not associ‐
ated with severe spasticity is discouraged.
Topical lidocaine may be of an advantage for patients who complain of localized neuropathic 
pain [28]. Lidocaine decreases the frequency of Na+ channel opening, thereby decreasing pain 
transmission. When it is used topically, systemic absorption is decreased, which makes sys‐
temic adverse reactions very rare. Evidence for use in low back pain is lacking, but its use 
should be considered if a patient complains of localized neuropathic pain.
Patients who suffer from chronic low back pain are sometimes prescribed corticosteroids. 
Many different doses of prednisone and dexamethasone have been studied, but there is no 
general consensus on an effective dose or duration [27]. Many guidelines recommend the use 
of corticosteroids as no major study has shown long‐term efficacy. If they are used, a single 
injection or short duration should highly be emphasized due to severe side effects of chronic 
use including immunosuppression, metabolic disorders and GI bleeding.
Addition of an adjuvant medication should directly target a cause of pain (neuropathy, mus‐
cle spasm, etc.), and efficacy should be evaluated after initiation and periodically throughout. 
If a medication is found to not be efficacious, it should be removed or replaced. For additional 
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information, clinicians can refer to neuropathic pain guidelines that provide evidence‐based 
recommendations for specific disease state‐induced neuropathic pain [29]. If acute or chronic 
pain is completely neuropathic in nature, the WHO's stepwise ladder is not appropriate to 
follow and a medication regimen targeting neuropathy should be initiated.
7. Risk of opioids
After the addition of nonopioids and possible adjuvants, the WHO's analgesic ladder calls 
for low to strong opioids. However, if a patient is in severe acute pain, it is reasonable to start 
therapy with all three types of analgesics and then rapidly de‐escalate to a lower step on the 
analgesic ladder [9]. When treating chronic pain, opioids should never be utilized as first‐line 
agents outside of cancer or palliative care. Opioids have only been shown in the literature 
to have a short‐term improvement in pain and carry a high risk for serious side effects and 
possibly even death [6]. Before initiating therapy, clinicians and patients should have a dis‐
cussion regarding expected goals and potential risks. Goals should include how efficacy will 
be measured for both pain relief and functionality and what measures will indicate contin‐
ued treatment. Patients should also be informed that opioids only show a short‐term benefit 
in relieving pain and long‐term efficacy is lacking. Expectations should be that opioids will 
likely never provide complete relief.
The addition of opioids to a chronic pain regimen should be considered carefully. Patients do 
not need to fail nonopioids or adjuvants prior to initiating opioids, benefits must simply out‐
weigh the risks of starting opioid therapy [1, 8]. Another way to consider this is that opioids 
should be considered in patients with severe disabling pain that is likely not to be relieved 
from nonopioids and adjuvants alone. The worst risks are with overdose and potentially 
fatal respiratory depression. Overdose risk is dose dependent, and clinicians should be care‐
ful when doses are escalated. This is particularly important as there is technically no ceiling 
dose for opioids. Several other factors increase the risk for opioid‐related overdose including 
methadone use, co‐prescription with benzodiazepines, history of sleep‐disordered breathing, 
reduced renal or hepatic function, increased age, pregnancy, history of substance abuse and 
psychiatric illness. Additionally, the risk of opioid‐related overdose is elevated when starting 
patients on opioid therapy with long‐acting or extended release formulations. For this reason, 
these dosage forms should only be utilized in opioid‐tolerant patients. Risk mitigation strate‐
gies such as checking prescription refill history, urine drug screening and use of medications 
specifically for opioid use disorders (methadone, buprenorphine) increase retention in opioid 
treatment programs.
Prior to starting opioid therapy, the prescriber must fully understand the concepts of 
opioid abuse (opioid misuse disorders), tolerance and physical withdrawal [6]. Opioid 
abuse or opioid misuse disorders are described by patterned misuse of opioids that 
include unsuccessful attempts to curb use and results in social problems at home, work 
or school. Tolerance is simply a diminished response to a fixed dose of medication with 
repeated use. Physical dependence is when a medication causes the body to change in a 
way that when the medication is removed the body produces withdrawal symptoms. Both 
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physical dependence and tolerance can occur in the absence of opioid abuse. When treating 
a patient, it is necessary to keep these concepts separate and not to assume that because a 
patient is requiring higher doses of medication or is experiencing withdrawal symptoms 
that they are abusing opioids. Only after considering all of these things, a prescriber should 
initiate opioid therapy.
Opioid medications typically exert their analgesic effects through agonism at μ‐, δ‐ and ĸ‐opi‐
oid receptors [33, 34]. Opioid receptors are g‐coupled protein receptors and are most com‐
monly Gi/Go. Once these g‐coupled protein receptors are activated, they decrease adenylyl 
cyclase activity, decrease calcium conductance and inhibit excitatory neurotransmission. This 
slows the transmission of pain that impulses both centrally and peripherally. Opioids activate 
centrally located receptors that play a key role in descending pain pathways and peripher‐
ally in the spinal cord. This spinal cord transmission regulates the relay of nociceptive pain 
inputs from the periphery to the brain. While all three opioid receptors mediate analgesia, 
activation of individual receptors will produce different effects [33]. μ‐opioid receptors lower 
respiratory depression, sedation, euphoria, nausea, constipation and urinary retention. δ‐opi‐
oid agonists have similar effects to those of μ‐opioid agonists. These effects include respira‐
tory depression, constipation and euphoria. While μ‐ and δ‐opioid agonists have very similar 
effects, ĸ‐opioid agonists have several unique effects. These agents can cause dysphoric, seda‐
tive, diuretic and sometimes aversive effects. An understanding of what receptor an indi‐
vidual opioid will activate will give the provider information in the common side effects that 
the medication will exhibit.
When acute or chronic low back pain necessitates the need to escalate to a weak opioid, 
the practitioner has several options to choose from. Drugs that are considered weak opi‐
oids are codeine, hydrocodone and oxycodone when used in combination with nonopioids 
(sometimes also tramadol), and all other full agonists (morphine, hydromorphone, oxyco‐
done alone, oxymorphone and fentanyl) are considered moderate of strong opioids [15]. 
Weak opioids should be initiated with caution if the patient already is taking paracetamol 
at a fixed interval as it increases the risk of overdose. When starting opioid therapy with the 
intent to continue its long term, this initial phase should be considered a trial and should 
only be continued or escalated if pain relief occurs [6]. If a patient fails an initial trial of 
opioids, other agents should be considered for refractory pain. Once on opioid regimen is 
started, the practitioner should periodically assess the need to continue opioid therapy. If 
tolerance occurs or pain relief is reduced, the clinician should weight escalating therapy to 
a moderate or strong opioid versus the increase in risk. It is reasonable to abandon opioid 
therapy if, after an escalation in therapy, the patient does not experience an increase in anal‐
gesic effect.
8. Opioids
It is believed that opium was cultivated in Mesopotamia as early as 3400 BC [35]. Natural occur‐
ring opiates are the alkaloid compounds found in the poppy plant and include morphine and 
codeine while the term opioid refers to any compound that binds to opioid receptors. Narcotic 
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originally was used to describe a medication that causes sleep, but the common misuse of drugs 
like quaaludes and barbiturates along with opioids caused this to become an umbrella term for 
drugs that are commonly abused. It is even used in a legal sense to describe the drugs of abuse. 
Even though opioids are grouped together, they have a wide range effects and each medication 
has unique properties (Table 2). There are four major opioid classes, and understanding each 
of the groups allows for easier prescribing as efficacy and side effects are similar within classes.
Drug name pertinent dosage 
forms
Equianalgesic 
oral dose (mg)
Starting oral 
dose (mg)
Dosing interval (h) Comments
Morphine Immediate 
release
extended release 
(Ms contin and 
kadian)
30 30–60 Immediate release: 
4–6
Extended‐release: 
8–24
Several different 
extended‐release 
formulations each 
with their own 
dosing interval 
recommendations
Strong opioid
Codeine Immediate 
release 
(combination 
with 
paracetamol)
200 30–60 4–6 Only available in 
combination with 
paracetamol
Weak opioid
Hydromorphone Immediate 
release
Extended release
7.5 4–8 Immediate release: 
4–6
Extended release: 
12–24
Several different 
extended release 
formulations each 
with their own 
dosing interval 
recommendations
Strong opioid
Hydrocodone Immediate 
release
(combination 
with 
paracetamol)
30 5–7.5 4–6 Only available in 
combination with 
paracetamol
Weak opioid
Oxymorphone Immediate 
release
Extended release
10 5–10 Immediate release: 
4–6
Extended release: 
12
Strong opioid
Oxycodone Immediate 
release
(alone and 
combination with 
paracetamol)
Extended release
20 15–30 Immediate release: 
4–6
Extended release: 
12
Can use lower 
starting doses if using 
combination product 
with paracetamol
Weak opioid 
(combination product)
Strong opioid
(when used alone at 
higher doses)
Fentanyl Transdermal;
Submucosal
– 0.025 Transdermal: 24
Submucosal:
Use only in patients 
suffering from severe 
chronic pain
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The phenanthrenes are one of the larger classes of opioids and contain the prototypical opioid 
morphine. This class contains the most commonly used opioids including morphine, codeine, 
hydrocodone, hydromorphone, oxycodone, oxymorphone, levorphanol, buprenorphine, nal‐
buphine and butorphanol [35]. A majority of these agents are metabolized in the liver by 
the CYP450 isoenzyme CYP2D6. Some even require metabolism to exert analgesic effects. 
For example, codeine itself has no analgesic effect in its original state, and it is only through 
metabolism by CYPD6 to morphine that it can produce an analgesic effect [36]. A similar 
process happens to both hydrocodone and oxycodone to be converted to hydromorphone 
and oxymorphone. Similar to codeine, hydrocodone has been proposed to be a prodrug and 
its analgesic effect is dependent on activation by CYP2D6. Oxycodone, on the other hand, is 
a μ‐opioid agonist and does not require activation by CYP2D6. A serious issue arises with 
the fact that CYP2D6 has a very dramatic range of activity from one person to the next. It has 
been reported in literature that through a mutation, some patients have no activity of CYP2D6 
(codeine produces no analgesic effect) whatsoever while others may be classified as ultrar‐
apid metabolizers. This may explain the wide range of reported efficacy in patients who are 
prescribed codeine‐ and hydrocodone‐containing products.
Another common attribute of drugs in the phenanthrene class is that they are typically gluc‐
uronidated and eliminated via the kidneys. This is especially important for morphine whose 
glucuronidated metabolite, morphine‐6‐gucuronide, is responsible for its analgesic effects 
[37]. In young and healthy individuals, this is not of importance, but in elderly or those with 
markedly reduced renal function, morphine's analgesic effects are prolonged. Morphine 
prescribed at fixed intervals in this patient population should be closely monitored as the 
respiratory side effects may accumulate as the medication is cleared more and more slowly. 
Additionally, drugs in this class with a 6‐hydroxyl group (morphine and codeine) are associ‐
ated with a higher incidence of nausea than those in the class that do not [35].
Drug name pertinent dosage 
forms
Equianalgesic 
oral dose (mg)
Starting oral 
dose (mg)
Dosing interval (h) Comments
Levorphanol Immediate 
release
4 2–4 6–8 Half‐life of 12–16 h; 
Good long‐acting agent 
for those that cannot 
tolerate morphine or 
methadone
Methadone Immediate 
release
Variable 2.5 
(analgesic)
10–20 
(withdrawal)
For analgesic 
effects: every 8 h
To prevent 
withdrawal: every 
24 h
Morphine (mg)/
methadone (mg) 
conversion changes 
as total daily doses of 
morphine increase
0–29 mg: 2/1
30–99 mg: 4/1
100–299 mg: 8/1
300–499 mg: 12/1
500–999 mg: 15/1
>1000 mg: 20/1
Table 2. Properties of common opioids.
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Phenlyperidines include the agents’ fentanyl, alfentanil, sufentanil and meperidine. Of these, 
fentanyl has the highest affinity for the μ‐opioid receptor and is 80–100 times that of mor‐
phine [35, 37]. While incredibly potent fentanyl has a very short half‐life leading to a short 
duration of action. Fentanyl's only advantage is that is highly lipophilic leading to its ability 
to be utilized nontraditional dosage forms. One of these dosage forms is the transdermal 
patch. Fentanyl transdermal patches should only be used in the most extreme cases of chronic 
low back pain. This dosage form possesses many nuances, and a complete understanding of 
them should be obtained before prescribing. When a fentanyl transdermal system is placed 
on a patient, it takes 6–12 h before taking effect [37]. Additionally, it will take 3–6 days to 
reach steady state and when removed a reservoir of drug will remain in effect up to 24 h. 
This makes initiating and weaning incredibly difficult and therefore should not be commonly 
done. Fentanyl also has a submucosal dosage form that may be beneficial in patients who suf‐
fer from acute breakthrough pain. The clinically applicability of this makes sense because of 
fentanyl's high potency and short duration of action. It is important to stress that this should 
not be prescribed on a regular basis and should only be utilized as a rescue medication in 
very rare cases. The majority of patients with chronic low back pain should not be prescribed 
fentanyl, but in rare circumstances, it may have clinical utility.
The other opioids in the phenlyperidine class should not be used in the treatment of low 
back pain. Meperidine is a relatively weak opioid agonist with poor oral absorption that 
fell out of favor due to its neurotoxic and anticholinergic side effects [23, 37]. Its metabolite 
normeperidine accumulates in patients with renal insufficiency and lowers seizure threshold. 
Additionally, it has significant drug‐drug interactions with monoamine oxidase inhibitors 
that lead to severe respiratory depression. The other agents that are sufentanil and alfentanil 
in this drug class have little to no role in the treatment of low back pain due to their short 
duration and lack of specialized dosage forms.
The remaining classes of opioids consist of the benzomorphans and the diphenylheptanes. 
The only agent in the benzomorphan class is pentazocine, which is a mixed opioid agonist‐
antagonist. The diphenylheptaines include propoxyphene and methadone. While metha‐
done has established itself in a highly specific role, propoxyphene has fallen out of favor 
dramatically [16]. Propoxyphene is thought to be no more efficacious than paracetamol, and 
it has a plethora of side effects. It has been associated with dizziness, weakness, paradoxical 
excitement, falls, visual disturbances and insomnia [35]. Propoxyphene itself is thought to act 
directly on the central nervous system and increase the risk for seizure activity which ulti‐
mately leads to the product being pulled off the market in the United States.
Several opioids have mixed agonist‐antagonist activity and have only a limited role in the 
treatment of pain. These drugs provide small analgesic effects in patients with little or no prior 
opioid exposure and may exacerbate withdrawal symptoms in patients who have a physical 
dependence on opioid medications [35, 37]. Drugs in this group are pentazocine, butorphanol 
and nalbuphine. These agents have a ceiling effect on both analgesia and respiratory depres‐
sion and have limited abuse potential. As doses escalate so do the antagonistic effects against 
other opioids. This places the patient at risk for withdrawal. Also, the risk for psychotomi‐
metic side effects (delirium, delusions and hallucinations) increases in conjunction with the 
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dose [37]. Pentazocine has the highest incidence of these side effects. The role of these agents 
in pain is limited by their antagonistic effects and lack of convenient dosage forms. Only 
pentazocine is available in an oral dosage form and has fallen out of favor to treat acute or 
chronic pain. The partial agonist buprenorphine acts similarly to the agonist‐antagonists with 
the one caveat that it is not associated with psychotomimetic side effects. Similar to the ago‐
nist‐antagonists, it can produce withdrawal symptoms when administered to patients taking 
high doses of other opioid medications. It is also combined with naloxone to reduce the risk 
of abuse. Buprenorphine is available as a sublingual dosage form in the United States and a 
transdermal extended release system in Europe. The sublingual form is commonly used in the 
United States in addiction treatment programs.
Methadone is another opioid with a unique mechanism of action other than being a μ‐opioid 
receptor agonist. This mechanism may be particularly advantageous for patients who have 
“opioid‐resistant” pain states or have a neuropathic component to their pain [37]. Similar 
to some of the agents to treat neuropathy, the R‐isomer of methadone is antagonistic at the 
NMDA receptor and may be beneficial in treating the effects of hyperalgesia and allodynia 
seen in chronic pain states [37]. Methadone should be used with caution as mentioned before 
its use increases the risk for overdose and a misunderstanding of its pharmacokinetics and 
pharmacodynamics perpetuates this effect. The terminal half‐life of the drug is typically 
thought to be 15–60 h, but has been cited as up to 120 h [38]. Because of this, it may take a 
week or longer to reach steady state, and therefore, the drug should be titrated no more often 
than weekly. Additionally, the analgesic effect of methadone is roughly 4–8 h and should be 
dosed on an every 8‐h interval. Due to this discrepancy, the drug has a high risk for accumu‐
lation and may put the patient at risk for sedation, confusion, respiratory depression, cardiac 
abnormalities and death. The general consensus is that a dose of 2.5 mg every 8 h is a safe 
starting dose for opioid‐naive patients [38]. Careful monitoring should be performed on any 
patient starting on methadone. Another caveat to dosing methadone is that it has a nonlinear 
equianalgesic conversion. This means that patients on higher doses of opioids are more sen‐
sitive to the effects of methadone and when converting the ratio of morphine equivalents to 
methadone dose decreases. However, with caution, the practitioner can utilize this effect to 
their advantage in treating the most complicated of patients.
Lastly, there are two agents that are sometimes considered opioid analgesics, but have both 
opioid and nonopioid mechanisms. These two agents are tramadol and tapentadol. While 
both have activity at the μ‐opioid receptor, this activity alone does not equate to the full 
analgesic effects seen with these agents [35, 39]. The remainder of their analgesic effects can 
be attributed to the inhibition of serotonin and norepinephrine reuptake. Similar to TCAs, 
this may be useful in treating neuropathic pain and caution should be used when combining 
therapy with other antidepressants or medications that increase the levels of serotonin as it 
increases the risk for serotonin syndrome [29]. Tramadol can be used for mild‐to‐moderate 
pain, but it should not be used as monotherapy when opioids are indicated based on the 
severity of pain. Tramadol's analgesic effect is at most equal to codeine and is probably less 
than that of hydrocodone [13, 16]. The maximum dose of tramadol is 100 mg every 6 h. Higher 
doses than 400 mg a day should not be used as it increases the risk for lethargy, nausea, tachy‐
cardia, agitation and hypertension. Additionally, tramadol has a neuroexcitatory effect so as 
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doses increase so does the risk for seizures [13]. For these reasons, tramadol should be used 
either as an adjuvant medication or prior to stepping up to moderate or strong opioid‐con‐
taining regimens and is often seen as adjunct medications.
9. Conclusion
By blending together all of the concepts in this chapter, a practitioner can provide the best 
treatment for their patients suffering from low back pain. Through an understanding of a 
modified WHO's stepwise approach and a thorough understanding of all of the drug class 
available to them, they should be able to escalate and de‐escalate therapy in a safe and effec‐
tive manner. The practitioner will need to set expectations, incorporate a multimodal treat‐
ment approach, analyze potential contraindications for specific drug therapy and provide the 
most ideal medication regimen. This regimen should be based on ease and appropriateness 
for the individual patient and should be executed with a complete understanding of every 
drug class mentioned in this chapter (paracetamol, NSAIDs, adjuvant and opioid medica‐
tions). If this is done, the practitioner will truly be in expert in the pharmacologic manage‐
ment of low back pain.
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